EE184 Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom
Abstract
Authors
Mohammed Soomro Baran Ufuktepe Nicola Tilt Flore Decuypere Elide Toniolo Angela Blake Sandeep Kiri Rémi Marty